Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-masked trial of OCS-01 eye drops in diabetic macular edema
2021-005173-95Phase 2Active
- Sponsor
- Oculis
- Start
- Jul 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OCS-01 in diabetic macular edema (DME), sponsored by Oculis. Primary endpoints: Stage 1 primary endpoint and Stage 2 endpoints. Started Jul 2022; status: active.
02
Drugs
OCS-01
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2021-005173-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005173-95.